SCHEMBL15058771

SCHEMBL15058771

CC(C)(C)OC(=O)NOC(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.50
PPARA Q07869 1/20 0.50
POLB P06746 1/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
ADRB2 P07550 2/20 0.48
ADRB1 P08588 2/20 0.48
ADRB3 P13945 2/20 0.48
NR1H4 Q96RI1 1/20 0.48
PKM P14618 1/20 0.47
MAPT P10636 3/20 0.46
MAPK1 P28482 2/20 0.46
TSHR P16473 1/20 0.46
CES1 P23141 1/20 0.45
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2616111 0.83 MAPK1 (0.56) POLBKMT2AMEN1ADRB2ADRB1
SCHEMBL6900510 0.81 GAA (0.48) PPARGPPARAKMT2APKMMAPT
SCHEMBL12067919 0.80 TDP1 (0.52) PPARGPPARAPOLBKMT2AADRB2
SCHEMBL11526123 0.80 KCNJ1 (0.52) POLBKMT2AMEN1ADRB2ADRB1
SCHEMBL15058988 0.80 TDP1 (0.58) POLBKMT2AMEN1PKMMAPK1
SCHEMBL10014142 0.79 MAPT (0.46) PPARGPPARAKMT2AMEN1NR1H4
SCHEMBL15588625 0.79 MAPT (0.55) PPARGPPARAPOLBKMT2AMEN1
SCHEMBL14344864 0.79 CA12 (0.44) PPARGPPARAPOLBKMT2AMAPT
SCHEMBL13595532 0.79 KMT2A (0.44) POLBKMT2AMEN1ADRB2ADRB1
SCHEMBL13595527 0.79 CA1 (0.44) POLBKMT2AMAPTALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794603-B1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-06-15 EP disclosed
EP-2794603-B1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-06-15 EP disclosed
US-9181248-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-11-10 US disclosed
US-9181248-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-11-10 US disclosed
US-9181248-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-11-10 US disclosed
US-20150105420-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2015-04-16 US disclosed
US-20150105420-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2015-04-16 US disclosed
US-20150105420-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2015-04-16 US disclosed
US-8940761-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-01-27 US disclosed
US-8940761-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-01-27 US disclosed
US-8940761-B2 [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-01-27 US disclosed
US-20140329853-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2014-11-06 US disclosed
US-20140329853-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2014-11-06 US disclosed
US-20140329853-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2014-11-06 US disclosed
EP-2794603-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2014-10-29 EP disclosed
WO-2013092739-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-06-27 WO disclosed
WO-2013092739-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329853-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3A, PDE2A PPARG 2451/4885PPARA 2783/4885POLB 1714/4885
US-20150105420-A1 [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3A, PDE2A PPARG 2451/4885PPARA 2783/4885POLB 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.